136 related articles for article (PubMed ID: 9916907)
1. Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Krupova Y; Novotny J; Sabo A; Mateicka F; Krcmery V
Int J Antimicrob Agents; 1998 Nov; 10(4):313-6. PubMed ID: 9916907
[TBL] [Abstract][Full Text] [Related]
2. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis.
Spanik S; Trupl J; Kunova A; Botek R; Sorkovska D; Grey E; Studena M; Lacka J; Oravcova E; Krchnakova A; Rusnakova V; Svec J; Krupova I; Grausova S; Stopkova K; Koren P; Krcmery V
Scand J Infect Dis; 1997; 29(3):245-9. PubMed ID: 9255883
[TBL] [Abstract][Full Text] [Related]
3. Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia.
Persson L; Vikerfors T; Sjöberg L; Engervall P; Tidefelt U
Scand J Infect Dis; 2000; 32(6):615-21. PubMed ID: 11200370
[TBL] [Abstract][Full Text] [Related]
4. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
5. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients.
Spanik S; Trupl J; Kunova A; Drgona L; Salek T; Mardiak J; Kukuckova E; Studena M; Pichna P; Oravcova E; Grey E; Koren P; Svec J; Lacka J; Sufliarsky J; Krcmery V
J Med Microbiol; 1997 Jun; 46(6):517-23. PubMed ID: 9350206
[TBL] [Abstract][Full Text] [Related]
6. Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
Krupova I; Kaiserova E; Foltinova A; Kovacicova G; Kiskova M; Krchnakova A; Kunova A; Trupl J; West D; Krcmery V
J Chemother; 1998 Jun; 10(3):236-42. PubMed ID: 9669650
[TBL] [Abstract][Full Text] [Related]
7. [Bacteremia due to vancomycin-resistant enterococci in neutropenic cancer patients].
Marron A; Carratalà J; Ayats J; Fernández de Sevilla A; Domínguez MA; Liñares J; Gudiol F
Med Clin (Barc); 1998 Dec; 111(20):761-4. PubMed ID: 9922964
[TBL] [Abstract][Full Text] [Related]
8. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.
Carratalá J; Alcaide F; Fernández-Sevilla A; Corbella X; Lińares J; Gudiol F
Clin Infect Dis; 1995 May; 20(5):1169-73. PubMed ID: 7619995
[TBL] [Abstract][Full Text] [Related]
9. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer.
Viscoli C; Moroni C; Boni L; Bruzzi P; Comelli A; Dini G; Fabbri A; Secondo V; Terragna A
Rev Infect Dis; 1991; 13(3):397-404. PubMed ID: 1866542
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Craig M; Cumpston AD; Hobbs GR; Devetten MP; Sarwari AR; Ericson SG
Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients.
Snyder M; Pasikhova Y; Baluch A
Cancer Control; 2021; 28():10732748211045593. PubMed ID: 34558349
[TBL] [Abstract][Full Text] [Related]
14. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case controlled study.
Krcméry V; Spanik S; Krupova I; Trupl J; Kunova A; Smid M; Pichnova E
J Chemother; 1998 Aug; 10(4):320-5. PubMed ID: 9720472
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].
Delarive P; Baumgartner JD; Glauser MP; Cometta A
Schweiz Med Wochenschr; 2000 Dec; 130(48):1837-44. PubMed ID: 11132527
[TBL] [Abstract][Full Text] [Related]
16. Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin.
Dompeling EC; Donnelly JP; Deresinski SC; Feld R; Lane-Allman EF; De Pauw BE
Eur J Cancer; 1996 Jul; 32A(8):1332-9. PubMed ID: 8869095
[TBL] [Abstract][Full Text] [Related]
17. Bacteremia and fungemia occurring during antimicrobial prophylaxis with ofloxacin in cancer patients: risk factors, etiology and outcome.
Spanik S; Trupl J; Ilavska I; Helpianska L; Drgona L; Demitrovicova A; Kukuckova E; Studena M; Pichna P; Oravcova E; Rusnakova V; Koren P; Lacka J; Krcmery V
J Chemother; 1996 Oct; 8(5):387-93. PubMed ID: 8957720
[TBL] [Abstract][Full Text] [Related]
18. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
19. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
Fanci R; Paci C; Martinez RL; Fabbri A; Pecile P; Leoni F; Longo G
J Chemother; 2000 Jun; 12(3):232-9. PubMed ID: 10877519
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.
De Pauw BE; Deresinski SC; Feld R; Lane-Allman EF; Donnelly JP
Ann Intern Med; 1994 May; 120(10):834-44. PubMed ID: 8154643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
